Implementation of cancer genomics into the clinic is becoming a reality. Personalised medicine or "Precision medicine" as some authors refer to it, uses molecular data from a specific patient to guide clinical decisions such as prevention, diagnosis and treatment. This will revolutionise healthcare and will play a dominant role in the future of cancer therapy. Bioinformatics analyses are essential to identify patients who will benefit from treatment based on their molecular profile, and to tailor chemotherapeutic regimens accordingly.
The aim of this course is to present a complete computational pipeline for the analysis and interpretation of Next-Generation Sequencing (NGS) data, such as exome sequencing or targeted panels that are commonly used in the clinic.
We will address the implementation of large-scale genomic sequencing in clinical practice and recently developed computational strategies for the analysis of NGS data. Particular emphasis will be placed on the interpretation of results, selection of biomarkers for drug responses and affording opportunities to match therapies with the characteristics of individual patient tumours.
Case studies will be used to illustrate the principles of how genetics has influenced the refinement of diagnoses and personalised treatment of cancer disease.
Javier Perales and
IMPORTANT DATES for this Course:
Deadline for applications: Nov 16th 2015
Latest notification of acceptance: Nov 17th 2015
Course dates: Nov 30th 2015 to Dec 3rd 2015
TBHD15 Course duration: 4 days TBHD15 Course Fee: Euro 360.00